BioAge Labs, Inc.

BIOA Nasdaq SEC CIK 1709941
Follow BioAge Labs Weekly email: filings, results, news

Financials

Reported figures only · latest: Q2 2026 USD · US GAAP
Revenue, last quarter $2.5M +1.6% vs same quarter last year
Net income −$26.1M −21% vs same quarter last year
EPS, diluted −$0.58 +3.3% vs same quarter last year
Operating cash flow −$19.3M +3.6% vs same quarter last year
Revenue by quarter
$0
$0
$1.5M
$2.4M
$2.1M
$3.1M
$2.8M
$2.5M
Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income4 fiscal years
−$100M−$75M−$50M−$25M$0FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$80.6M
FY24−$71.1M
FY23−$63.9M
FY22-
Free cash flowOperating cash flow minus capital expenditure
−$100M−$75M−$50M−$25M$0FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$82.3M
FY24−$51.9M
FY23−$37.5M
FY22-

News

No stories filed under BioAge Labs yet - coverage appears here as the news feed clusters it.